WHITE BEAR LAKE, MINNESOTA, UNITED STATES — February 17, 2026 Envoy Medical announced that enrollment in its pivotal clinical trial evaluating the fully implanted Acclaim Cochlear Implant is nearing completion, marking a major milestone in investigational hearing restoration technology. To date, 45 of the targeted 56 patients have been successfully implanted and enrolled, representing more than 80% of total study enrollment. The company expects full enrollment by the end of March 2026, keeping the study on track for completion and a potential Premarket Approval (PMA) submission to the U.S. Food and Drug Administration in 2027.
Science Significance
The Acclaim cochlear implant represents a next-generation advancement in auditory prosthetics through its fully implanted architecture and proprietary piezoelectric sensor technology. Unlike conventional cochlear implants that rely on external microphones and processors, the Acclaim system leverages the natural anatomy of the ear to capture sound internally. This design aims to improve sound fidelity, user comfort, and continuous hearing capability without reliance on externally worn components. Scientifically, the technology introduces a differentiated signal capture pathway that may enhance auditory perception in patients with severe to profound sensorineural hearing loss who derive limited benefit from hearing aids.
Regulatory Significance
The pivotal trial is being conducted to generate the clinical safety and effectiveness data required for U.S. FDA Premarket Approval (PMA) — the most rigorous regulatory pathway for high-risk implantable medical devices. The investigational system previously received Breakthrough Device Designation, reflecting regulatory recognition of its potential to address unmet clinical needs. Enrollment progression is a critical regulatory milestone, as pivotal implant studies must demonstrate long-term device performance, surgical safety, and functional hearing outcomes. Continued advancement toward PMA submission underscores compliance with device clinical investigation standards, design controls, and post-implant monitoring frameworks.
Business Significance
Advertisement
For Envoy Medical, nearing enrollment completion represents a significant operational and commercial inflection point. Pivotal trial execution is one of the most resource-intensive phases of device commercialization, requiring coordinated surgical sites, follow-up monitoring, and data validation. Successful completion positions the company to transition from investigational development into regulatory review and eventual market entry. The Acclaim implant also expands Envoy Medical’s fully implanted hearing portfolio, complementing its Esteem® active middle ear implant, and reinforcing its strategic focus on differentiated implantable hearing technologies.
Patients’ Significance
From a patient perspective, the Acclaim system addresses long-standing usability and lifestyle limitations associated with traditional cochlear implants. External components can create barriers related to comfort, cosmetic visibility, maintenance, and continuous wear. A fully implanted system may enable 24/7 hearing capability, improved convenience, and enhanced quality of life. For adults with severe to profound hearing loss who are not adequately supported by hearing aids, the technology could represent a transformative alternative that restores auditory access while reducing device management burdens.
Policy Significance
Hearing loss remains a major global public health concern, with growing policy emphasis on accessibility to advanced auditory care technologies. Breakthrough-designated implantable systems align with regulatory and healthcare priorities focused on innovation, functional restoration, and long-term patient outcomes. As reimbursement bodies increasingly evaluate value-based outcomes for implantable devices, technologies that improve compliance, usability, and hearing performance may play a larger role in future coverage and adoption frameworks.
With enrollment expected to conclude by March 2026, Envoy Medical is advancing steadily toward a defining milestone in implantable hearing innovation. The Acclaim cochlear implant’s fully implanted design, combined with its novel sound capture technology, signals a paradigm shift in cochlear implant engineering. As pivotal data mature and regulatory pathways progress, the device has the potential to redefine standards of care for patients with severe hearing loss while expanding the clinical and commercial frontier of fully implanted auditory prosthetics.
Source: Envoy Medical press release
